RxDoctor Payments Data

Glenn Taylor, MD

Family Medicine · Novi, MINPI 1689675878

Payments from drug & device makers

$1,399in general payments, 2019–2025

Across 87 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$267
  • Novo Nordisk$238
  • Amgen$200
  • Pfizer$149
  • AstraZeneca$91
  • Teva Pharmaceuticals USA, Inc.$67
  • plus $388 from 14 others

What the payments were for

  • Food & beverage$1,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,399 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$38,627
Medicare patients
133
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$69,387
JardianceEmpagliflozin32$53,988
TrulicityDulaglutide31$51,267
FarxigaDapagliflozin Propanediol24$39,815
RybelsusSemaglutide26$35,232
XareltoRivaroxaban28$30,117
EliquisApixaban25$29,021
LinzessLinaclotide19$18,700
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,129
Breo ElliptaFluticasone/Vilanterol26$15,885
ElmironPentosan Polysulfate Sodium14$14,111
MyrbetriqMirabegron12$5,511
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,689
Epinephrine12$3,600
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$238$104,61965 claims
AstraZenecaFarxiga$91$39,81524 claims
Johnson & JohnsonXarelto$267$30,11728 claims
PfizerEliquis$149$29,02125 claims
GSKBreo Ellipta, Shingrix$52$18,71039 claims
AbbVieLinzess$52$18,70019 claims
Astellas Pharma US IncMyrbetriq$22$5,51112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →